Skip to main content
Scientific Reports logoLink to Scientific Reports
. 2024 Oct 17;14:24370. doi: 10.1038/s41598-024-76253-9

Author Correction: ABBV-744 as a potential inhibitor of SARS-CoV-2 main protease enzyme against COVID-19

Zeynab Fakhar 1,#, Shama Khan 2, Suliman Y AlOmar 3, Afrah Alkhuriji 3, Aijaz Ahmad 2,4,
PMCID: PMC11487162  PMID: 39420077

Correction to: Scientific Reports https://doi.org/10.1038/s41598-020–79918-3, published online 08 January 2021.

This Article contains errors.

In the Introduction,

“Among them, the structural proteins, membrane (M), envelope (E), nucleocapsid (N), hemagglutinin-esterase (HE) and spike (S) proteins contribute notably in viral transmission and replication in the host cells7.”

should read:

“Among them, the structural proteins, membrane (M), envelope (E), nucleocapsid (N) and spike (S) proteins contribute notably in viral transmission and replication in the host cells7.”

Additionally, Reference 7 is incorrectly given as:

Shanmugaraj, B., Siriwattananon, K., Wangkanont, K. & Phoolcharoen, W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac. J. Allergy Immunol. 38, 10–18 (2020).

The correct reference is listed below:

Sharma, A., Tiwari, V. & Sowdhamini, R. Computational search for potential COVID-19 drugs from FDA-approved drugs and small molecules of natural origin identifies several anti-virals and plant products. J Biosci 45, 100 (2020). 10.1007/s12038-020-00069-8.

These changes do not affect the conclusions of the Article.


Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES